Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : AbbVie Inc
Deal Size : $1,000.0 million
Deal Type : Partnership
Frontier Announces Milestone Payment in AbbVie Partnership for Advancing Lead Candidates
Details : Under the partnership, the companies will collaborate on the research and pre-clinical development of programs directed to novel E3 ligases, and certain immunology and oncology targets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 23, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : AbbVie Inc
Deal Size : $1,000.0 million
Deal Type : Partnership
Lead Product(s) : FMC-376
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Deep Track Capital
Deal Size : $100.0 million
Deal Type : Series C Financing
Frontier Medicines Appoints Gerardo Ubaghs as CFO, Announces $20M Series C Extension
Details : The financing proceeds will support further advancement of Frontier’s FMC-376, a small molecule. Currently, it is being evaluated for the treatment of advanced solid tumors With KRAS G12C mutations.
Brand Name : FMC-376
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 25, 2024
Lead Product(s) : FMC-376
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Deep Track Capital
Deal Size : $100.0 million
Deal Type : Series C Financing
Lead Product(s) : FMC-376
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Deerfield Management Company
Deal Size : $80.0 million
Deal Type : Financing
Details : The financing proceeds will support the advancement of multiple wholly-owned pipeline programs into clinical studies, including FMC-376 for the treatment of advanced solid tumors with KRAS G12C Mutations.
Brand Name : FMC-376
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 22, 2024
Lead Product(s) : FMC-376
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Deerfield Management Company
Deal Size : $80.0 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : AbbVie Inc
Deal Size : $1,000.0 million
Deal Type : Partnership
Details : Under the partnership, Frontier Medicine and Abbvie will collaborate on the research and pre-clinical development of programs directed to novel E3 ligases, and certain immunology and oncology targets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : AbbVie Inc
Deal Size : $1,000.0 million
Deal Type : Partnership
Lead Product(s) : FMC-376
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In preclinical studies, FMC-376 retains potency in the context of receptor tyrosine kinase activation, which is likely a major mechanism of non-response and resistance to prior generation inhibitors that only target inactive (GDP-bound) KRASG12C.
Brand Name : FMC-376
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Lead Product(s) : FMC-376
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study was conducted in preclinical models that are both sensitive (NCI-H358 and MIA PaCa-2) and resistant (NCI-H2122) to first-generation KRASG12C inhibitors (adagrasib and sotorasib). While first-generation inhibitors were less effective in the NCI-...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
March 09, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : AbbVie Inc
Deal Size : $1,100.0 million
Deal Type : Collaboration
Details : Under the multi-year collaboration, AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $55.0 million
December 02, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : AbbVie Inc
Deal Size : $1,100.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?